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NigeriaAbstract Objective: This study determined the effect of adherence to highly active antiretroviral
therapy (HAART) on body mass index (BMI) and immunological and virological parameters of
people living with HIV/AIDS (PLWHA) attending University College Hospital, Ibadan.
Methodology: Prospective cohort of consenting PLWHA was followed up for a minimum of
3 months, had their drug adherence determined using pharmacy records and self-reporting. The
sociodemographic data, weight, height, plasma viral load and CD4 count were recorded at baseline
and 3 months. These data were entered into the computer and analyzed.
Results: A total of 318 PLWHA with a median age of 38 ± 9.6 years participated. Fifty-four per-
cent were female. Sixty-three percent were 95% adherent to HAART. Most (99.4%) were on non-
nucleoside reverse transcriptase inhibitor-based therapy. There was a remarkable fall in viral load to
non-detectable levels among adherent compared with non-adherent PLWHA. Furthermore, there
was a signiﬁcant increase in CD4 count among adherent compared with non-adherent PLWHA.
Adherent clients showed marked improvement in BMI and immunological and virological status.
Conclusion: Adherence to HAART reduced viral load to an undetectable level and increased CD4
count among adherent PLWHA on HAART.
ª 2015 The Authors. Alexandria University Faculty of Medicine. Production and hosting by Elsevier B.V.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/4.0/).
Table 1 Sociodemographic characteristics of respondents.
Socio-demographic
characteristics
Frequency
(N= 318)
Percentage
Age group (years)
15–19 3 1.0
20–29 42 13.2
30–39 130 40.9
40 and above 143 44.9
Marital status
Single 43 13.5
Married 212 66.7
Divorced 31 9.7
Widowed 32 10.1
Highest level of education
None 15 4.7
Primary 56 17.6
Secondary 144 45.3
Tertiary 103 32.4
Occupation
Unemployed 30 9.4
Trader 131 41.2
Civil servant 95 29.9
Artisan 42 13.2
Police/soldier 20 6.3
Ethnic group
Yoruba 251 78.9
Ibo 28 8.8
Hausa 12 3.8
Others 27 8.5
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HIV/AIDS has spread almost worldwide, with the majority of
people infected living in sub-Saharan Africa.1 Since 1986 when
the ﬁrst case in Nigeria was reported, the prevalence has
increased among antenatal clinic attendees from 1.8%
(1991), 5.8% (2001), 4.4% (2005), 4.6% (2008), and 4.1%
(2010).2,3
Highly active antiretroviral therapy (HAART) is the only
proven treatment of HIV and is provided free at the antiretro-
viral clinic, University College Hospital, Ibadan, Nigeria.4–6 It
consists of a combination of three or more drugs from at least
two different classes of antiretroviral (ARV) therapy.4,5 Good
adherence to therapy is the key to prevention of treatment fail-
ure, development of drug resistance and subsequent virological
and immunological failure.4,5
Although 100% adherence is desirable, various adherence
studies have reported that at least 95% of the doses should
be taken for an optimal response, while lesser degrees of adher-
ence are more often associated with virological failure.4,5,7 It
has been documented that people living with HIV/AIDS
(PLWHA) with good adherence have undetected viral loads
and increased CD4 counts, live longer, and have better quality
of life.4,5,7 This study was conducted to determine the effect of
HAART adherence on body mass index (BMI) and immuno-
logical and virological parameters of PLWHA attending
University College Hospital, Ibadan.
2. Materials and methods
The study site was the Antiretroviral (ARV) Clinic of the
University College Hospital (an 850-bed tertiary hospital),
Ibadan, Nigeria. The ARV clinic was one of 25 other ARV
clinics established and funded by the Federal Government
since 2002 to provide comprehensive HIV/AIDS care includ-
ing antiretroviral therapy initially at a subsidized rate. Since
2004, the President Bush’s Emergency Plan for AIDS Relief
(PEPFAR) provided support for the scale-up of the nation’s
antiretroviral treatment program. The services provided at
the ARV clinic became free since January, 2006. The ARV
Clinic opens daily from 8:00 a.m. to 5:00 p.m. Monday
through Thursday. The clinic serves the entire southwestern
part of Nigeria and beyond.6 HIV positive patients with
CD4 count 6350 cells/ll, AIDS deﬁning disease at any CD4
count, are recruited into the antiretroviral treatment program
while patients asymptomatic with CD4 count >350 cells/ll are
placed on supportive therapy.
A prospective cohort of drug naı¨ve PLWHA was com-
menced on antiretroviral drugs and followed up for 3 months
at the Antiretroviral Clinic, University College Hospital,
Ibadan, Nigeria. Informed consent was obtained from all
respondents while serial numbers and not names were used
to maintain conﬁdentiality. Patients with tuberculosis and
other comorbidities such as Diabetes mellitus and hyperten-
sion were excluded. Clinical checklist data such as sociodemo-
graphic information, weight, height, plasma viral load and
CD4 count at baseline (that is before commencement of
HAART) and at 3 months after commencement of HAART
were recorded. BMI at baseline and after 3 months was calcu-
lated using the formula = weight (kg)/height (m2). Undetected
viral load was deﬁned as <400 copies/ll (log viral load<2.6 copies/ll). The degree of adherence by individual
patients was estimated manually by patients’ drug pickup at
the clinic pharmacy and by patient self-report at a follow-up
session. The degree of adherence from patient self-reporting
was estimated using the following formula.4
% adherence over past 7 days¼doses should have taken#missed doses
doses should have taken
100%
From the formula, level of adherence by individual patients
was classiﬁed into those with <95% adherence and those with
P95% adherence.4 HAART-adherent patients were deﬁned in
this study as individuals with P95% adherence level.
The data were entered into a computer, cleaned, and sta-
tistical analysis was performed using SPSS version 12. Tables
of frequency were generated, and tests of signiﬁcance were
conducted using v2 test and paired t test. Tests were considered
signiﬁcant for a p value less than 0.05.
3. Results
Three hundred and eighteen consenting PLWHA participated
in the study. The respondents mean age was 39.1 years (SD:
9.6 years). Fifty-four percent were female. One hundred and
thirty (40.9%) belonged to the 30–39 years age group, and
77.7% had completed secondary education. The majority
(66.7%) was married and 131 (41.2%) were traders
(Table 1). Majority (90.3%) had AIDS.
Most (99.4%) were on non-nucleoside reverse transcriptase
inhibitor (NNRTI)-based therapy. The majority (89.9%) was
Table 3 Respondents’ CD4 count and viral load at baseline
and three month.
Frequency %
Baseline CD4 count (cells/ll)
6200 287 90.3
>201 31 9.7
CD4 count (3 month) (cells/ll)
6200 207 65.1
>201 111 34.9
Baseline log viral load (copies/ll)
>2.6 318 100
Log viral load (3 month) (copies/ll)
62.6 64 20.1
>2.6 254 79.9
Table 4 Relationship between level of adherence and type of
HAART at Ibadan.
Adherence level Drug therapy Total
NVP based EFV based PI based
<95% 99 (83.9%) 17 (14.4%) 2 (1.7%) 118 (37.1%)
P95% 187 (93.5%) 13 (6.5%) 0 (0%) 200 (62.9%)
Total 286 (89.9%) 30 (9.5%) 2 (0.6%) 318 (100%)
Chi square test: 9.069; p= 0.011.
Table 5 Relationship between adherence level and respon-
dents’ CD4 count and viral load at three month on HAART.
Variable Adherence level Total Statistic
<95% P95%
CD4 count (3 month)
6200 cells/ll 81 (39.1) 126 (60.9) 207 (100) 1.040; 0.308
>201 cells/ll 37 (33.3) 74 (66.7) 111 (100)
Log viral load (3 month)
62.6 copies/ll 40 (62.5) 24 (37.5) 64 (100) 22.138; 0.0001
>2.6 copies/ll 78 (30.7) 176 (69.3) 254 (100)
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containing regimen, and 0.6% on Kaletra (lopinavir/riton-
avir)-containing regimen (Table 2).
Table 3 shows low CD4 count in most respondents at base-
line (90.3%) while the proportion of respondents with low
CD4 count reduced by 3 months of HAART therapy
(65.1%). At baseline the viral load was high in all respondents
which reduced to undetectable level in one-ﬁfth of them by
3 months on HAART.
Sixty-three percent were P95% adherent to HAART.
Participants taking nevirapine were more likely to have
P95% than those taking Efavirenz-based regimens (93.5%
vs. 6.5%, p= 0.011) (Table 4).
Table 5 shows the relationship between HAART adherence
and respondents’ CD4 count and viral load at three month. A
higher proportion of adherent respondents had higher CD4
count and undetectable viral load. There was an increased sig-
niﬁcant relationship in the CD4 count from baseline to the
third month of evaluation. The viral load also indicated a sig-
niﬁcant relationship, with a decrease among the adherent
patient at the second evaluation. BMI also showed signiﬁcant
change during the second evaluation (Table 6).
4. Discussion
This study investigated the effect of HAART adherence on
immunological and virological status of PLWHA at the
ARV clinic, University College Hospital, Ibadan over a
3-month period. We found that 63% of the PLWHA were
adherent to HAART. Various previous studies have shown
that levels of adherence to HAART vary among PLWHA
worldwide, and that emphasis should be placed on 100%
adherence during counseling sessions, although 95% adher-
ence is sufﬁcient to suppress viral load to undetectable levels
and give optimal BMI response.3,4,7 The majority of adherent
patients had undetectable viral loads. This conﬁrms the need
for PLWHA to be adherent to HAART because an undetect-
able viral load guarantees improved immunological status and
quality of life.4,5,7
In the present study, we found that most participants were
on NNRTI-based therapy. This ﬁnding is in line with other
studies on adherence in resource-limited settings and such a
combination was found to be cost-effective among such pop-
ulations.8,9 Participants taking nevirapine-based regimens wereTable 2 Drug therapy of PLWHA at Ibadan.
HAART Frequency (N= 318) Percentage
d4T + 3TC+NVP 159 50.0
CBV+NVP 76 23.9
Truv + NVP 32 10.1
ddI + 3TC+ EFV 12 3.8
3TC+ ABC+NVP 11 3.5
CBV+ EFV 10 3.1
Truv + EFV 8 2.5
3TC+ TNF+NVP 8 2.5
LPV/r + CBV 2 0.6
d4T, stavudine; 3TC, lamivudine; NVP, nevirapine; CBV, Com-
bivir (lamivudine/zidovudine); Truv, Truvada (tenofovir/emtric-
itabine); ddI, didanosine; EFV, Efavirenz; ABC, abacavir; TNF,
tenofovir; LPV/r, Kaletra (lopinavir/ritonavir).also more likely to have P95% adherence than those taking
Efavirenz-based regimens. This contrasts with ﬁndings of
Adeyemi et al. in 2008 who reported that participants taking
Efavirenz-based regimens reported higher adherence to ther-
apy.10 This ﬁnding could have resulted from the low CD4
count of most respondents at commencement of therapy with
more people having more adverse effects to Efavirenz-based
regimens. PLWHA on nevirapine-based regimens therapy usu-
ally have more adverse effects to HAART at higher CD4
count.
However, the fact that PLWHA had viral suppression at
3 months showed that, with good adherence in a treatment-
naı¨ve population, the likelihood of treatment failure and drug
resistance is much reduced. It has been reported previously
that patients adhere to their drug regimen when they are well
informed about the drug combination, have a lower pill bur-
den, convenient timing, and fewer side effects.11–13
Table 6 Mean BMI, CD4 count and viral load and percent
change between baseline and 3 months in HAART adherent
and non-adherent PLWHA.
Variable Baseline
Mean ± SD
3 months
Mean ± SD
Percent change
and 95% CI
p
Value
Non-adherent PLWHA
BMI 21.6 ± 5.2 21.5 ± 5.5 0.13
(1.33, 1.06)
0.824
CD4
count
174.9 ± 152.8 359.7 ± 180.7 184.80
(155.71, 213.88)
0.001
Log viral
load
4.88 ± 0.89 3.17 ± 0.82 1.71
(1.93, 1.50)
0.001
Adherent PLWHA
BMI 22.2 ± 5.2 20.8 ± 5.1 1.46
(2.49, 0.42)
0.006
CD4
count
196.4 ± 185.0 357.7 ± 222.1 161.23
(131.40, 191.06)
0.001
Log viral
load
4.6 ± 1.1 3.8 ± 1.0 0.81
(0.99, 0.63)
0.001
54 S.A. Olowookere et al.The study also showed that drug-adherent patients had
improved immunological and virological outcomes when com-
pared with the non-adherent population. This is in line with
other studies on HAART adherence among drug-naı¨ve
populations.7,8,11,12
The study is among the few studies that assessed the effect
of HAART adherence on the outcome measured in a resource
limited setting. However, it is limited by the short period of
evaluation and adherence measurement by self report.
In conclusion, P95% adherence to HAART improved
PLWHA BMI, reduced viral loads to an undetectable level,
and increased CD4 counts. There is a need for ongoing adher-
ence counseling and monitoring of PLWHA on treatment.
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